A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
Public ClinicalTrials.gov record NCT05255601. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants With Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma
Study identification
- NCT ID
- NCT05255601
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 5 participants
Conditions and interventions
Conditions
Interventions
- Nivolumab Drug
- Relatlimab Drug
Drug
Eligibility (public fields only)
- Age range
- Up to 30 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 12, 2022
- Primary completion
- Dec 2, 2025
- Completion
- Dec 2, 2025
- Last update posted
- Feb 24, 2026
2022 – 2025
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0077 | Birmingham | Alabama | 35233 | — |
| Local Institution - 0024 | Phoenix | Arizona | 85016 | — |
| Local Institution - 0035 | Palo Alto | California | 94304 | — |
| Local Institution - 0032 | New Haven | Connecticut | 06510 | — |
| Local Institution - 0066 | Fort Myers | Florida | 33908 | — |
| Local Institution - 0073 | Baltimore | Maryland | 21287 | — |
| Local Institution - 0025 | Minneapolis | Minnesota | 55454 | — |
| Local Institution - 0020 | Jackson | Mississippi | 39216 | — |
| Local Institution - 0071 | Hackensack | New Jersey | 07601 | — |
| Local Institution - 0060 | New York | New York | 10032 | — |
| Local Institution - 0059 | Valhalla | New York | 10595 | — |
| Local Institution - 0029 | Austin | Texas | 78723 | — |
| Local Institution - 0026 | San Antonio | Texas | 78207 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 38 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05255601, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 24, 2026 · Synced May 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05255601 live on ClinicalTrials.gov.